دورية أكاديمية
أعرض في EDS

A novel microRNA signature for the detection of melanoma by liquid biopsy.

التفاصيل البيبلوغرافية
العنوان: A novel microRNA signature for the detection of melanoma by liquid biopsy.
المؤلفون: Sabato C; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy., Noviello TMR; Biogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', 83031, Ariano Irpino, Italy.; Department of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy., Covre A; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy.; Medical Oncology, Department of Molecular and Developmental Medicine, University of Siena, 53100, Siena, Italy., Coral S; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy.; Epigen Therapeutics s.r.l., 53100, Siena, Italy., Caruso FP; Biogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', 83031, Ariano Irpino, Italy.; Department of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy., Besharat ZM; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy., Splendiani E; Department of Molecular Medicine, Sapienza University, 00161, Rome, Italy., Masuelli L; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy., Battistelli C; Department of Molecular Medicine, Sapienza University, 00161, Rome, Italy., Vacca A; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy., Catanzaro G; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy., Po A; Department of Molecular Medicine, Sapienza University, 00161, Rome, Italy., Anichini A; Human Tumor Immunobiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, ENETS Center of Excellence, Milan, Italy., Maio M; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy.; Medical Oncology, Department of Molecular and Developmental Medicine, University of Siena, 53100, Siena, Italy., Ceccarelli M; Biogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', 83031, Ariano Irpino, Italy.; Department of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy., Di Giacomo AM; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy.; Medical Oncology, Department of Molecular and Developmental Medicine, University of Siena, 53100, Siena, Italy., Ferretti E; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy. elisabetta.ferretti@uniroma1.it.
المصدر: Journal of translational medicine [J Transl Med] 2022 Oct 15; Vol. 20 (1), pp. 469. Date of Electronic Publication: 2022 Oct 15.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2003-
مواضيع طبية MeSH: Circulating MicroRNA*/genetics , Melanoma*/diagnosis , Melanoma*/genetics , MicroRNAs*/genetics, Biomarkers, Tumor/genetics ; Gene Expression Profiling ; Humans ; Liquid Biopsy
مستخلص: Background: Melanoma is the deadliest form of skin cancer and metastatic disease is associated with a significant survival rate drop. There is an urgent need for consistent tumor biomarkers to scale precision medicine and reduce cancer mortality. Here, we aimed to identify a melanoma-specific circulating microRNA signature and assess its value as a diagnostic tool.
Methods: The study consisted of a discovery phase and two validation phases. Circulating plasma extracellular vesicles (pEV) associated microRNA profiles were obtained from a discovery cohort of metastatic melanoma patients and normal subjects as controls. A pEV-microRNA signature was obtained using a LASSO penalized logistic regression model. The pEV-microRNA signature was subsequently validated both in a publicly available dataset and in an independent internal cohort.
Results: We identified and validated in three independent cohorts a panel of melanoma-specific circulating microRNAs that showed high accuracy in differentiating melanoma patients from healthy subjects with an area under the curve (AUC) of 1.00, 0.94 and 0.75 respectively. Investigation of the function of the pEV-microRNA signature evidenced their possible immune suppressive role in melanoma patients.
Conclusions: We demonstrate that a blood test based on circulating microRNAs can non-invasively detect melanoma, offering a novel diagnostic tool for improving standard care. Moreover, we revealed an immune suppressive role for melanoma pEV-microRNAs.
(© 2022. The Author(s).)
References: J Stat Softw. 2010;33(1):1-22. (PMID: 20808728)
N Engl J Med. 2019 Aug 15;381(7):626-636. (PMID: 31166680)
Int J Biol Sci. 2022 Jan 24;18(4):1491-1507. (PMID: 35280687)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Cancers (Basel). 2020 Jun 25;12(6):. (PMID: 32630542)
Nat Rev Genet. 2019 Feb;20(2):71-88. (PMID: 30410101)
Cell. 2015 May 21;161(5):1046-1057. (PMID: 26000481)
F1000Res. 2014 Aug 05;3:183. (PMID: 26500764)
BMC Cancer. 2018 Apr 18;18(1):439. (PMID: 29669525)
Cell Metab. 2019 Oct 1;30(4):656-673. (PMID: 31447320)
Clin Cancer Res. 2021 Sep 1;27(17):4737-4745. (PMID: 34112708)
Lancet Oncol. 2019 Sep;20(9):1239-1251. (PMID: 31345627)
Nat Biotechnol. 2017 Sep;35(9):872-878. (PMID: 28829439)
Mol Med Rep. 2016 Jan;13(1):994-1002. (PMID: 26647877)
J Cell Physiol. 2019 Feb 5;:. (PMID: 30723916)
J Extracell Vesicles. 2018 Feb 15;7(1):1435138. (PMID: 29511460)
EMBO Mol Med. 2012 Mar;4(3):143-59. (PMID: 22351564)
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228. (PMID: 29339798)
J Clin Invest. 2016 Apr 1;126(4):1139-43. (PMID: 27035805)
BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208)
Cell J. 2020 Oct;22(3):386-393. (PMID: 31863665)
N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797)
Nat Biotechnol. 2008 Apr;26(4):462-9. (PMID: 18362881)
Oncogene. 2013 Mar 21;32(12):1549-59. (PMID: 22641218)
PLoS One. 2017 Dec 6;12(12):e0189165. (PMID: 29211799)
Cancers (Basel). 2020 Nov 13;12(11):. (PMID: 33202891)
Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891)
J Clin Med. 2015 Dec 17;4(12):2012-27. (PMID: 26694476)
Clin Cancer Res. 2019 Dec 15;25(24):7351-7362. (PMID: 31530631)
J Exp Med. 2019 May 6;216(5):1091-1107. (PMID: 30975896)
Cell Death Differ. 2016 Mar;23(3):484-95. (PMID: 26337669)
Eur J Cancer. 2020 Feb;126:33-44. (PMID: 31901705)
Life Sci Alliance. 2019 Mar 7;2(2):. (PMID: 30846484)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. (PMID: 12434020)
Clin Res Hepatol Gastroenterol. 2020 Feb;44(1):101-114. (PMID: 31255531)
EBioMedicine. 2020 Dec;62:103119. (PMID: 33242827)
Biosci Rep. 2018 Jun 21;38(3):. (PMID: 29871972)
Melanoma Res. 2018 Aug;28(4):295-303. (PMID: 29750752)
Neoplasma. 2020 Mar;67(2):267-276. (PMID: 31847527)
Biomed Pharmacother. 2019 Jul;115:108944. (PMID: 31082771)
Arch Pathol Lab Med. 2014 Jun;138(6):828-32. (PMID: 24878024)
Cell. 1996 Aug 23;86(4):531-42. (PMID: 8752208)
Clin Cancer Res. 2021 Oct 1;27(19):5225-5235. (PMID: 34158360)
Cancers (Basel). 2020 Feb 13;12(2):. (PMID: 32069911)
Drug Deliv Transl Res. 2014 Feb;4(1):19-30. (PMID: 25786615)
Front Genet. 2013 May 24;4:94. (PMID: 23745127)
Sci Rep. 2016 Jan 20;6:19413. (PMID: 26786760)
Sci Rep. 2020 Jan 9;10(1):92. (PMID: 31919420)
Bioinformatics. 2009 Dec 15;25(24):3325-6. (PMID: 19808880)
Wiley Interdiscip Rev RNA. 2021 Nov;12(6):e1662. (PMID: 33998154)
Med Sci (Basel). 2021 Oct 20;9(4):. (PMID: 34698235)
Cell Death Dis. 2020 Mar 30;11(3):210. (PMID: 32231206)
Med Oncol. 2016 Aug;33(8):88. (PMID: 27389544)
Cancers (Basel). 2021 Jun 09;13(12):. (PMID: 34207514)
فهرسة مساهمة: Keywords: Biomarkers signature; Diagnosis; Extracellular vesicles; Liquid biopsy; Melanoma; microRNAs
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Circulating MicroRNA)
0 (MicroRNAs)
تواريخ الأحداث: Date Created: 20221015 Date Completed: 20221018 Latest Revision: 20221107
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9571479
DOI: 10.1186/s12967-022-03668-1
PMID: 36243798
قاعدة البيانات: MEDLINE
الوصف
تدمد:1479-5876
DOI:10.1186/s12967-022-03668-1